The remission status of AML patients post alloSCT is associated with a distinct single-cell bone marrow T cell signature.

Mathioudaki A, Wang X, Sedloev DN, Huth R, Kamal A, Hundemer M, Liu Y, Vasileiou S, Lulla PD, Müller-Tidow C, Dreger P, Luft T, Sauer T, Schmitt M, Zaugg JB, Pabst C

Blood, 2024

doi:10.1182/blood.2023021815.

Human and mouse neutrophils share core transcriptional programs in both homeostatic and inflamed contexts.

Hackert NS, Radtke FA, Exner T, Lorenz HM, Müller-Tidow C, Nigrovic PA, Wabnitz G, Grieshaber-Bouyer R

Nature communications, 2023

doi:10.1038/s41467-023-43573-9.

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations.

Zhao D, Rohde C, Göllner S, Zhou F, Pauli C, Blank MF, Zinz R, Grab AL, Poos AM, John L, Huhn S, Raab MS, Müller-Tidow C, Weinhold N

Leukemia, 2023

doi:10.1038/s41375-023-02060-2.

Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial.

Liebers N, Bruch PM, Terzer T, Hernandez-Hernandez M, Paramasivam N, Fitzgerald D, Altmann H, Roider T, Kolb C, Knoll M, Lenze A, Platzbecker U, Röllig C, Baldus C, Serve H, Bornhäuser M, Hübschmann D, Müller-Tidow C, Stölzel F, Huber W, Benner A, Zenz T, Lu J, Dietrich S

Nature cancer, 2023

doi:10.1038/s43018-023-00645-5.

The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia.

Allert C, Müller-Tidow C, Blank MF

International journal of cancer, 2023

doi:10.1002/ijc.34684.

The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia.

Weidenauer K, Schmidt C, Rohde C, Pauli C, Blank MF, Heid D, Waclawiczek A, Corbacioglu A, Göllner S, Lotze M, Vierbaum L, Renders S, Krijgsveld J, Raffel S, Sauer T, Trumpp A, Pabst C, Müller-Tidow C, Janssen M

Leukemia, 2023

doi:10.1038/s41375-023-01951-8.

Clonal hematopoiesis with DNMT3A and PPM1D mutations impairs regeneration in autologous stem cell transplant recipients.

Stelmach P, Richter S, Sauer S, Fabre MA, Gu M, Rohde C, Janssen M, Liebers N, Proynova R, Weinhold N, Raab MS, Goldschmidt H, Besenbeck B, Pavel P, Laier S, Trumpp A, Dietrich S, Vassiliou GS, Müller-Tidow C

Haematologica, 2023

doi:10.3324/haematol.2023.282992.

Comparing the value of mono- versus coculture for high-throughput compound screening in hematological malignancies.

Herbst SA, Kim V, Roider T, Schitter EC, Bruch PM, Liebers N, Kolb C, Knoll M, Lu J, Dreger P, Müller-Tidow C, Zenz T, Huber W, Dietrich S

Blood advances, 2023

doi:10.1182/bloodadvances.2022009652.

Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine/venetoclax.

Waclawiczek A, Leppä AM, Renders S, Stumpf K, Reyneri C, Betz B, Janssen M, Shahswar R, Donato E, Karpova D, Thiel V, Unglaub JM, Grabowski S, Gryzik S, Vierbaum L, Schlenk RF, Röllig C, Hundemer M, Pabst C, Heuser M, Raffel S, Müller-Tidow C, Sauer T, Trumpp A

Cancer discovery, 2023

doi:10.1158/2159-8290.cd-22-0939.

Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia.

Beneyto-Calabuig S, Merbach AK, Kniffka JA, Antes M, Szu-Tu C, Rohde C, Waclawiczek A, Stelmach P, Gräßle S, Pervan P, Janssen M, Landry JJM, Benes V, Jauch A, Brough M, Bauer M, Besenbeck B, Felden J, Bäumer S, Hundemer M, Sauer T, Pabst C, Wickenhauser C, Angenendt L, Schliemann C, Trumpp A, Haas S, Scherer M, Raffel S, Müller-Tidow C, Velten L

Cell stem cell, 2023

doi:10.1016/j.stem.2023.04.001.

Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis.

Zioni N, Bercovich AA, Chapal-Ilani N, Bacharach T, Rappoport N, Solomon A, Avraham R, Kopitman E, Porat Z, Sacma M, Hartmut G, Scheller M, Muller-Tidow C, Lipka D, Shlush E, Minden M, Kaushansky N, Shlush LI

Nature communications, 2023

doi:10.1038/s41467-023-36906-1.

Reduced proliferation of bone marrow MSC after allogeneic stem cell transplantation is associated with clinical outcome.

Katzerke C, Schaffrath J, Lützkendorf J, Janssen M, Merbach AK, Nerger K, Binder M, Baum C, Lauer K, Rohde C, Willscher E, Müller-Tidow C, Mueller LP

Blood advances, 2023

doi:10.1182/bloodadvances.2022008510.

A dynamic rRNA Ribomethylome drives stemness in acute myeloid leukemia.

Zhou F, Aroua N, Liu Y, Rohde C, Cheng J, Wirth AK, Fijalkowska D, Göllner S, Lotze M, Yun H, Yu X, Pabst C, Sauer T, Oellerich T, Serve H, Röllig C, Bornhäuser M, Thiede C, Baldus C, Frye M, Raffel S, Krijgsveld J, Jeremias I, Beckmann R, Trumpp A, Müller-Tidow C

Cancer discovery, 2023

doi:10.1158/2159-8290.CD-22-0210.

Proteogenomics refines the molecular classification of chronic lymphocytic leukemia.

Herbst SA, Vesterlund M, Helmboldt AJ, Jafari R, Siavelis I, Stahl M, Schitter EC, Liebers N, Brinkmann BJ, Czernilofsky F, Roider T, Bruch PM, Iskar M, Kittai A, Huang Y, Lu J, Richter S, Mermelekas G, Umer HM, Knoll M, Kolb C, Lenze A, Cao X, Österholm C, Wahnschaffe L, Herling C, Scheinost S, Ganzinger M, Mansouri L, Kriegsmann K, Kriegsmann M, Anders S, Zapatka M, Del Poeta G, Zucchetto A, Bomben R, Gattei V, Dreger P, Woyach J, Herling M, Müller-Tidow C, Rosenquist R, Stilgenbauer S, Zenz T, Huber W, Tausch E, Lehtiö J, Dietrich S

Nature communications, 2022

doi:10.1038/s41467-022-33385-8.

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.

Allert C, Waclawiczek A, Zimmermann SMN, Göllner S, Heid D, Janssen M, Renders S, Rohde C, Bauer M, Bruckmann M, Zinz R, Pauli C, Besenbeck B, Wickenhauser C, Trumpp A, Krijgsveld J, Müller-Tidow C, Blank MF

Leukemia, 2022

doi:10.1038/s41375-022-01687-x.

Venetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk Acute Myeloid Leukemia by suppressing MCL-1.

Janssen M, Schmidt C, Bruch PM, Blank MF, Rohde C, Waclawiczek A, Heid D, Renders S, Göllner S, Vierbaum L, Besenbeck B, Herbst SA, Knoll M, Kolb C, Przybylla A, Weidenauer K, Ludwig AK, Fabre MA, Gu M, Schlenk RF, Stölzel F, Bornhäuser M, Röllig C, Platzbecker U, Baldus CD, Serve H, Sauer T, Raffel S, Pabst C, Vassiliou GS, Vick B, Jeremias I, Trumpp A, Krijgsveld J, Müller-Tidow C, Dietrich S

Blood, 2022

doi:10.1182/blood.2021014241.

AKTing on XPO1 inhibition in AML.

Goellner S, Mueller-Tidow C

Nature cancer, 2022

doi:10.1038/s43018-022-00395-w.

Antigen presentation safeguards the integrity of the hematopoietic stem cell pool.

Hernández-Malmierca P, Vonficht D, Schnell A, Uckelmann HJ, Bollhagen A, Mahmoud MAA, Landua SL, van der Salm E, Trautmann CL, Raffel S, Grünschläger F, Lutz R, Ghosh M, Renders S, Correia N, Donato E, Dixon KO, Hirche C, Andresen C, Robens C, Werner PS, Boch T, Eisel D, Osen W, Pilz F, Przybylla A, Klein C, Buchholz F, Milsom MD, Essers MAG, Eichmüller SB, Hofmann WK, Nowak D, Hübschmann D, Hundemer M, Thiede C, Bullinger L, Müller-Tidow C, Armstrong SA, Trumpp A, Kuchroo VK, Haas S

Cell stem cell, 2022

doi:10.1016/j.stem.2022.04.007.

CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia.

He L, Arnold C, Thoma J, Rohde C, Kholmatov M, Garg S, Hsiao CC, Viol L, Zhang K, Sun R, Schmidt C, Janssen M, MacRae T, Huber K, Thiede C, Hébert J, Sauvageau G, Spratte J, Fluhr H, Aust G, Müller-Tidow C, Niehrs C, Pereira G, Hamann J, Tanaka M, Zaugg JB, Pabst C

EMBO molecular medicine, 2022

doi:10.15252/emmm.202114990.

Ageing and interferon gamma response drive the phenotype of neutrophils in the inflamed joint.

Grieshaber-Bouyer R, Exner T, Hackert NS, Radtke FA, Jelinsky SA, Halyabar O, Wactor A, Karimizadeh E, Brennan J, Schettini J, Jonsson H, Rao DA, Henderson LA, Müller-Tidow C, Lorenz HM, Wabnitz G, Lederer JA, Hadjipanayis A, Nigrovic PA

Annals of the rheumatic diseases, 2022

doi:10.1136/annrheumdis-2021-221866.

CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.

Liu Y, Wang S, Schubert ML, Lauk A, Yao H, Blank MF, Cui C, Janssen M, Schmidt C, Göllner S, Kleist C, Zhou F, Rahfeld JU, Sauer T, Schmitt M, Müller-Tidow C

International journal of cancer, 2021

doi:10.1002/ijc.33865.

Epitranscriptomic modifications in acute myeloid leukemia: m 6 A and 2'- O-methylation as targets for novel therapeutic strategies.

Pauli C, Kienhöfer M, Göllner S, Müller-Tidow C

Biological chemistry, 2021

doi:10.1515/hsz-2021-0286.

Phagocytosis by stroma confounds coculture studies.

Herbst SA, Stolarczyk M, Becirovic T, Czernilofsky F, Liu Y, Kolb C, Knoll M, Herling M, Müller-Tidow C, Dietrich S

iScience, 2021

doi:10.1016/j.isci.2021.103062.

Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response.

Scheller M, Ludwig AK, Göllner S, Rohde C, Krämer S, Stäble S, Janssen M, Müller JA, He L, Bäumer N, Arnold C, Gerß J, Schönung M, Thiede C, Niederwieser C, Niederwieser D, Serve H, Berdel WE, Thiem U, Hemmerling I, Leuschner F, Plass C, Schlesner M, Zaugg J, Milsom MD, Trumpp A, Pabst C, Lipka DB, Müller-Tidow C

Nature cancer, 2021

doi:10.1038/s43018-021-00213-9.

Selective elimination of immunosuppressive T cells in patients with multiple myeloma.

Awwad MHS, Mahmoud A, Bruns H, Echchannaoui H, Kriegsmann K, Lutz R, Raab MS, Bertsch U, Munder M, Jauch A, Weisel K, Maier B, Weinhold N, Salwender HJ, Eckstein V, Hänel M, Fenk R, Dürig J, Brors B, Benner A, Müller-Tidow C, Goldschmidt H, Hundemer M

Leukemia, 2021

doi:10.1038/s41375-021-01172-x.

The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: an analysis of the MCL Younger and Elderly trial.

Roider T, Wang X, Hüttl K, Müller-Tidow C, Klapper W, Rosenwald A, Stewart JP, Gonzalez de Castro D, Dreger P, Hermine O, Kluin-Nelemans HC, Grabe N, Dreyling M, Pott C, Ott G, Hoster E, Dietrich S

International journal of cancer, 2020

doi:10.1002/ijc.33202.

A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.

Wass M, Göllner S, Besenbeck B, Schlenk RF, Mundmann P, Göthert JR, Noppeney R, Schliemann C, Mikesch JH, Lenz G, Dugas M, Wermke M, Röllig C, Bornhäuser M, Serve H, Platzbecker U, Foerster KI, Burhenne J, Haefeli WE, Müller LP, Binder M, Pabst C, Müller-Tidow C, Study Alliance Leukemia (SAL)

Leukemia, 2020

doi:10.1038/s41375-020-0892-z.

Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels.

Roider T, Seufert J, Uvarovskii A, Frauhammer F, Bordas M, Abedpour N, Stolarczyk M, Mallm JP, Herbst SA, Bruch PM, Balke-Want H, Hundemer M, Rippe K, Goeppert B, Seiffert M, Brors B, Mechtersheimer G, Zenz T, Peifer M, Chapuy B, Schlesner M, Müller-Tidow C, Fröhling S, Huber W, Anders S, Dietrich S

Nature cell biology, 2020

doi:10.1038/s41556-020-0532-x.

Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for acute myeloid leukemia cell proliferation.

Pauli C, Liu Y, Rohde C, Cui C, Fijalkowska D, Gerloff D, Walter C, Krijgsveld J, Dugas M, Edemir B, Pabst C, Müller LP, Zhou F, Müller-Tidow C

Blood, 2020

doi:10.1182/blood.2019004121.

Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML.

Garg S, Reyes-Palomares A, He L, Bergeron A, Lavallée VP, Lemieux S, Gendron P, Rohde C, Xia J, Jagdhane P, Müller-Tidow C, Lipka DB, Imren S, Humphries RK, Waskow C, Jeremias I, Vick B, Hébert J, Richard-Carpentier G, Sauvageau G, Zaugg J, Barabé F, Pabst C

Blood, 2019

doi:10.1182/blood.2018862383.